caa a22 4500 475819268 CHVBK 20180406123818.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1007/s002280000213 doi (NATIONALLICENCE)springer-10.1007/s002280000213 Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia [Elektronische Daten] [D.N. Kiortsis, H. Millionis, E. Bairaktari, M.S. Elisaf] Abstract.: Objectives: In patients with mixed lipid disorders, monotherapy may not effectively control all lipid abnormalities. We undertook this study to assess the efficacy of fenofibrate in combination with atorvastatin in patients with severe mixed dyslipidemia. Methods: This was an 18-week, open-label study conducted in our lipid clinic. After a 6-week dietary baseline phase, patients received 200mg/day micronised fenofibrate for 6weeks. At the end of this period the subjects discontinued this treatment and received 40mg/day atorvastatin for 6weeks. Finally 200mg/day of micronised fenofibrate was added to the statin therapy. Results: Administration of micronised fenofibrate reduced serum triglycerides (P<0.01) and total cholesterol and low-density lipoprotein (LDL) cholesterol (P<0.05 for both parameters), while it evoked a significant increase in serum high-density lipoprotein (HDL) cholesterol levels (P<0.05). Atorvastatin monotherapy induced a more pronounced decrease of total and LDL cholesterol. However, plasma triglycerides, although significantly lower than baseline values (P<0.05), were higher than the values observed during treatment with fenofibrate. Moreover, serum HDL cholesterol concentrations were higher during fibrate therapy than during the statin one. During the combination therapy, the decrease in triglycerides was greater than that observed with fenofibrate alone, while the decrease in LDL cholesterol was more pronounced than that observed with atorvastatin alone. Conclusion: The combination of atorvastatin with micronised fenofibrate in patients with severe mixed dyslipidemia may have a favourable effect on some major coronary artery disease risk factors. Springer-Verlag, 2000 Mixed lipid disorders Atorvastatin Micronised fenofibrate nationallicence Kiortsis D.N. Department of Internal Medicine and Biochemistry Laboratory, Medical School, University of Ioannina, Ioannina, Greece aut Millionis H. Department of Internal Medicine and Biochemistry Laboratory, Medical School, University of Ioannina, Ioannina, Greece aut Bairaktari E. Department of Internal Medicine and Biochemistry Laboratory, Medical School, University of Ioannina, Ioannina, Greece aut Elisaf M.S. Department of Internal Medicine and Biochemistry Laboratory, Medical School, University of Ioannina, Ioannina, Greece aut European Journal of Clinical Pharmacology Springer-Verlag 56/9-10(2000-12-01), 631-635 0031-6970 56:9-10<631 2000 56 228 https://doi.org/10.1007/s002280000213 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000213 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kiortsis D.N. Department of Internal Medicine and Biochemistry Laboratory, Medical School, University of Ioannina, Ioannina, Greece aut NATIONALLICENCE 700 1- Millionis H. Department of Internal Medicine and Biochemistry Laboratory, Medical School, University of Ioannina, Ioannina, Greece aut NATIONALLICENCE 700 1- Bairaktari E. Department of Internal Medicine and Biochemistry Laboratory, Medical School, University of Ioannina, Ioannina, Greece aut NATIONALLICENCE 700 1- Elisaf M.S. Department of Internal Medicine and Biochemistry Laboratory, Medical School, University of Ioannina, Ioannina, Greece aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 56/9-10(2000-12-01), 631-635 0031-6970 56:9-10<631 2000 56 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer